Perspectives

 
 

  • Sep 2 2022 This Week in Cardiology   A second ESC review covering REVIVED, the DANCAVAS CV screening trial, DELIVER on dapagliflozin in HF with mildly reduced EF, and the INVICTUS trial of rivaroxaban in rheumatic heart disease.
  • ESC 2022 DELIVERing the Details on Dapagliflozin in Heart Failure   Drs Pina and Solomon discuss the DELIVER trial presented at the European Society of Cardiology and whether all patients with heart failure should get SGLT2 inhibitors regardless of ejection fraction.
  • Bias and Other Barriers to HSCT Access Bias, defined as a prejudice in favor of or against a specific treatment on the part of physicians and patients, has not been carefully studied in the realm of cellular therapies.
  • Monkeypox Vaccines: Q&A With the CDC's Agam Rao, MD Two vaccines are available for monkeypox. A CDC vaccine expert answers questions about their effectiveness and dosing.
  • Time to Re-evaluate Herbal Supplements? The death of Lori McClintock is focusing attention on the use of nutritional supplements. Dr Caroline Apovian offers insight on unregulated supplements and ways clinicians can help patients.
  • The Protein Question in Plant-based Diets Lifestyle medicine physician Cate Collings addresses common myths about plant and animal protein sources.
  • A Resident's View: Low Nurse Staffing Spurs Unsafe Outcomes Nurses are overworked and legislation is slow to change that, compromising patient care and forcing new doctors in training to take up the slack.
  • ESC 2022 Judicious CVD Screening May Work in Men: DANCAVAS Comprehensive cardiac screening in men over 65 years seemed to be of benefit but the Danish setting may be key, writes John Mandrola, MD. Would U.S. screeners be as conservative with their interventions?
  • Paxlovid Rebound in COVID-19: Where We Stand on Drug Regimens   Drs Robert Glatter and Paul Auwaerter discuss Paxlovid rebound and recommendations for patients with COVID-19.
  • One Thing You Can Do to Be a Better Antimicrobial Steward The World Health Organization has declared that antimicrobial resistance is one of the top ten global public health threats. So what can you do to become a better antimicrobial steward?
  • A Better Way to Help Patients Drop Excess Weight   No target weights and greater comfort in prescribing anti-obesity medicines are among this expert's strategy.
  • Would You Like to Live to a 'Ripe Old Age'? We can control much about our quality of life, our length of life, and parameters of dying, by our volitional actions. Here's my advice.
  • ESC 2022 Should Aspirin Be the Second-Line Antiplatelet in CAD?   From European Society of Cardiology 2022, Drs O'Donoghue and Valgimigli discuss the latest analysis suggesting that for single antiplatelet therapy in patients with CAD, P2Y12 inhibitors beat aspirin.
  • DANCAVAS: Might Cardiovascular Screening Extend Men's Lives?   Drs Melissa Walton-Shirley and Axel Diederichsen discuss the DANCAVAS trial and the impact of screening for cardiovascular disease in men over 60 years.
  • Kicking the Can Neurologist Allan Block notes that politicians currently favor a strategy of "kicking the can down the road" when it comes to Medicare concerns. "But we're running out of road to kick it down," he says.
  • Is the Phrase 'A Cure for Cancer' Outdated?   WebMD's Chief Medical Officer, John Whyte, MD, speaks with Sanjay Juneja, MD, Chief of Oncology, Baton Rouge General Hospital, about multiple strategies and treatments for cancer and why the phrase 'a cure for cancer' might be outdated.
  • Death Is Not an Alternate Universe, in Cancer or COVID-19 Oncology has something to teach us about our response to death and dying.
  • Disparities in Monkeypox Show Missed Opportunities Monkeypox cases continue to increase across the country, and there remains great uncertainty about the future of this new public health crisis. Lessons from COVID could have prevented this crisis.
  • Future at Risk: Strategic Screening   Alabama psychologists partner with primary care colleagues to offer curbside consultation that improves diagnosis for depression and ensures adequate treatment.
  • How Long Do COVID Antibodies Last in Kids vs Adults?   A study looks at the durability of neutralizing antibodies after COVID infection in children compared with adults.